New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
08:22 EDTALXNAlexion at an excellent entry point, says RW Baird
Baird is increasingly confident in Alexion's Solaris prospects both near and long-term. The firm also noted the company's robust pipeline and current valuation and remains buyers of the shares for a recovery into the $125 range. Shares are Outperform rated.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
06:01 EDTALXNAlexion's Strensiz receives marketing approval in Japan
Alexion announced that Japanís Ministry of Health, Labour and Welfare approved the companyís New Drug Application for the use of Strensiq as a treatment for patients in Japan with hypophosphatasia, a life-threatening, ultra-rare metabolic disorder. Strensiq, a bone-targeted enzyme replacement therapy, is the first therapy approved in Japan for the treatment of patients with HPP. Alexion expects that initial patients with HPP in Japan will start commercial treatment with Strensiq by late Q3 2015.
June 26, 2015
07:13 EDTALXNAlexion receives CHMP positive opinions for Strensiq, Kanuma in the EU
Subscribe for More Information
June 23, 2015
06:32 EDTALXNAlexion completes acquisition of Synageva
Subscribe for More Information
June 22, 2015
06:33 EDTALXNAlexion accepts shares of Synageva tendered into exchange offer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use